Expression of PPARδ in multistage carcinogenesis of the colorectum: implications of malignant cancer morphology
Authors:
Open Access
- 12 September 2006
- journal article
- research article
- Published by Springer Nature in British Journal of Cancer
- Vol. 95 (7) , 889-895
Abstract
Whether peroxisome proliferator-activated receptor (PPAR) δ is a good target for the chemoprevention and/or treatment of colorectal cancer (CRC) remains controversial. Our goal was to examine PPARδ expression in multistage carcinogenesis of the colorectum and to assess the relevance of PPARδ in CRC. Immunohistochemical analysis indicated that PPARδ expression increased from normal mucosa to adenomatous polyps to CRC. In cancer tissues, the PPARδ protein was accumulated only in those cancer cells with highly malignant morphology, as represented by a large-sized nucleus, round-shaped nucleus, and presence of clear nucleoli. Interestingly, the cancer tissue often contained both PPARδ-positive and -negative areas, each retaining their respective specific morphological features. Moreover, this pattern persisted even when PPARδ-positive and -negative cells were aligned next to each other within a single cancer nest or gland and was present in the majority of CRC cases. Immunohistochemistry for Ki-67 proliferation marker showed no significant correlation between Ki-67 and PPARδ in CRC samples. Based on Western blot analysis and quantitative RT–PCR, high PPARδ protein expression correlated with high PPARδ mRNA levels. Peroxisome proliferator-activated receptor δ may have a supporting role in tumorigenesis, and the close association between PPARδ expression and malignant morphology of CRC cells suggests a pivotal role in cancer tissue.Keywords
This publication has 44 references indexed in Scilit:
- Quantitative analysis of PPARδ mRNA by real-time RT-PCR in 86 rectal cancer tissuesEuropean Journal of Surgical Oncology, 2006
- Protective effect of nonsteroidal anti-inflammatory drugs on colorectal adenomas is modified by a polymorphism in peroxisome proliferator-activated receptor δPharmacogenetics and Genomics, 2006
- No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARδ and PPARγ act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinomaPharmacogenetics and Genomics, 2005
- Wnt and Cyclooxygenase-2 Cross-talk Accelerates Adenoma GrowthCell Cycle, 2004
- PPARδ status and Apc-mediated tumourigenesis in the mouse intestineOncogene, 2004
- JTE-522, a cyclooxygenase-2 inhibitor, is an effective chemopreventive agent against rat experimental liver fibrosisGastroenterology, 2003
- How a Growth Control Path Takes a Wrong Turn to CancerScience, 1998
- Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factorCell, 1994
- Nuclear shape as a prognostic discriminant in colorectal carcinomaDiseases of the Colon & Rectum, 1991
- Genetic Alterations during Colorectal-Tumor DevelopmentNew England Journal of Medicine, 1988